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ttp://dx.doi.org/10.1016/j.ajpath.2013.04.029Aberrant proliferation of mesangial cells (MCs) is a key ﬁnding in progressive glomerular disease.
TH1177 is a small molecule that has been shown to inhibit low-voltage activated T-type Ca2þ channels
(TCCs). The current study investigates the effect of TH1177 on MC proliferation in vitro and in vivo. The
effect of Ca2þ channel inhibition on primary rat MC proliferation in vitro was studied using the
microculture tetrazolium assay and by measuring bromodeoxyuridine incorporation. In vivo, rats with
Thy1 nephritis were treated with TH1177 or vehicle. Glomerular injury and average glomerular cell
number were determined in a blinded fashion. Immunostaining for Ki-67 and phosphorylated ERK were
also performed. The expression of TCC isoforms in healthy and diseased tissue was investigated using
quantitative real-time PCR. TCC blockade caused a signiﬁcant reduction in rat MC proliferation in vitro,
whereas L-type inhibition had no effect. Treatment of Thy1 nephritis with TH1177 signiﬁcantly reduced
glomerular injury (P < 0.005) and caused a 49% reduction in glomerular cell number (P < 0.005)
compared to the placebo. TH1177 also reduced Ki-67-positive and pERK-positive cells per glomerulus by
52% (P < 0.01 and P < 0.005, respectively). These results demonstrate that TH1177 inhibits MC
proliferation in vitro and in vivo, supporting the hypothesis that TCC inhibition may be a useful strategy
for studying and modifying MC proliferative responses to injury. (Am J Pathol 2013, 183: 391e401;
http://dx.doi.org/10.1016/j.ajpath.2013.04.029)Supported by funding from the Medical Research Council and King’s
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structural components of the healthy glomerulus. In normal
adult kidney, MCs are relatively quiescent, with autoradio-
graphic studies demonstrating a glomerular cell renewal rate
of only 1%.1 In response to a variety of injurious stimuli, the
phenotype of these cells changes, leading to an increase in
proliferative rate and progressive matrix accumulation,
which can lead to overt glomerulosclerosis if left unchecked.
These features are seen in diseases such as IgA nephropathy
and diabetic nephropathy, which are two of the leading
causes of end-stage renal disease. Current therapies focus on
limiting the initiating insult and on blockade of the renin-
angiotensin system.2 Therapies that target the response of
MCs to the initial disease trigger may provide additional
beneﬁt in slowing the progression of chronic kidney disease.
Numerous different mitogenic signals have been impli-
cated in triggering this switch to an activated MC pheno-
type, but a consistent early step is a transient rise instigative Pathology.
.intracellular Ca2þ concentration. This has been shown to be
dependent on an inﬂux of Ca2þ from the extracellular space,
but the molecular identity of the channels involved is
unclear.3 Although calcium channel blockers (CCBs) are
known to reduce MC proliferation in vitro, this action does
not correlate with the blockade of high voltage-activated
L-type channels (LCCs) that are the traditional targets for
these agents.4 This suggests that CCBs exert their anti-
proliferative effect by interacting with a target other than
Cove-Smith et althe LCCs. T-type channels (TCCs) are low voltage-
activated, transient current Ca2þ channels with some struc-
tural homology to LCCs but with different activation
thresholds and kinetics. Three isoforms exist that differ in
the structure of their pore-forming a1 subunit and are known
as a1G, a1H, and a1I (or Cav3.1, Cav3.2, and Cav3.3,
respectively).5 Several lines of evidence link these channels
with the regulation of cell cycle progression in cancer cells,6
cardiac myocytes,7,8 and vascular smooth muscle cells.9 We
have previously reported the presence of a low-voltage
activated, transient calcium current, consistent with
a T-type current, in isolated human MCs.10 Others have
recorded similar currents in rat MCs.11 Human MCs express
mRNA for the Cav3.2 isoform alone. Pharmacological
inhibition of TCCs (but not LCCs) in vitro is anti-
proliferative in these cells, as is the knockdown of the
Cav3.2 isoform using siRNA.
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The effect of CCBs on animal models of glomerulo-
sclerosis is controversial, with varying outcomes according
to the disease model and the particular agent studied.12e14
One potential explanation is that CCBs differ in their
selectivity for TCCs or LCCs. TH1177 is a novel CCB, the
design of which incorporates key features of dihydropyr-
idines, benzothiazepines, and phenylalkylamines to enhance
its ability to block Ca2þ entry.6 This compound reduces the
proliferative rate of prostate cancer cells in vitro, with
a potency that correlates with its inhibition of calcium
inﬂux. Administration of TH1177 to mice inoculated with
human prostate cancer cells led to a signiﬁcant dose-
dependent increase in longevity.
In this study, we examined the effect of pharmacological
TCC inhibition on rat MC proliferation in vitro and on Thy1
nephritis in vivo. We also studied the expression of the
different TCC isoforms in healthy and diseased rat kidneys.
The results demonstrate that both Cav3.1 and Cav3.2 are
expressed at a similar level in normal renal cortex and the
expression of Cav3.2 mRNA increases with disease severity
in Thy1 nephritis. However, Cav3.1 is the main isoform
present in rat glomeruli and isolated MC, whereas Cav3.2
predominates in the extraglomerular cortex. TH1177
reduces rat MC proliferation in vitro with an apparent ED50
of 15 mmol/L. Treatment of animals with Thy1 nephritis
using TH1177 leads to a reduction in glomerular injury and
glomerular cell proliferation, which appears to be mediated
via suppression of ERK activation. Therefore, we conclude
that TH1177 is a useful tool for reducing MC proliferation
in vivo as well as in vitro. Further work delineating the exact
role of the individual TCC isoforms and their downstream
signaling pathways is of interest.
Materials and Methods
Reagents
All reagents were from Sigma-Aldrich (Gillingham, UK),
unless otherwise stated.392In Vitro Experiments
Primary rat MCs purchased from Dominion Pharmakine
(Bizkaia, Spain) were cultured in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) F-12 (Invitrogen, Paisley, UK),
supplemented with fetal calf serum, 100 IU/mL penicillin,
100 mg/mL streptomycin, and 2.5 mg/mL amphotericin (all
from Invitrogen). Cells from passage 5 to 15 were used in
experiments.
Calcium Channel Inhibitors
Verapamil and nickel chloride (NiCl2) were made up as 10
mmol/L aqueous solutions and were stored at 4C. TH1177
was made up as a 10 mmol/L solution in 100% ethanol and
was stored at 20C.
MTS Assay
Cell number was measured using the microculture tetrazo-
lium (MTS) assay (Promega, Southampton, UK). After
serum deprivation for 48 hours, cells were seeded into 96-
well plates at a density of 5000 cells per well and incubated
with 0 to 20 mmol/L TH1177 or 0 to 40 mmol/L verapamil
with 20% fetal calf serum. Absorbance at 490 nm was
measured at 24, 48, 72, and 96 hours in a microplate reader.
Experiments were repeated at least three times.
BrdU Incorporation
After 48 hours of serum deprivation, MC proliferation was
stimulated with 20% fetal calf serum, and drugs at a range of
concentrations were added for another 48 hours. Bromo-
deoxyuridine (BrdU) (ﬁnal concentration, 10 mmol/L) was
added for the ﬁnal 16 hours. Cells were washed with PBS,
ﬁxed for 45 minutes (3 volume 50 mmol/L glycine pH 2,
7 volume ethanol), washed, incubated in 4 M hydrochloric
acid for 10 minutes, and then blocked in 5% goat serum per
0.05% tween per PBS for 15 minutes before being incubated
overnight with monoclonal anti-BrdU antibody (1 in 100) at
4C. After a further three washes, the cells were incubated
with 5 mg/mL Alexa Fluor 555 goat anti-mouse antibody
(Invitrogen) at room temperature in the dark for 30 minutes.
Nuclei were counterstained with 10 mg/mL Hoechst 33342
for 15 minutes. Cells were visualized with a ﬂuorescence
microscope. A total of approximately 200 cells were
counted from at least four randomly chosen ﬁelds. Experi-
ments were repeated at least three times.
Apoptosis Assay
Quiescent rat MC were serum-stimulated in the presence or
absence of drugs as previously described for 24 hours.
Staurosporine (Sigma-Aldrich), at a ﬁnal concentration of
1 mmol/L, was added to one culture plate and incubated at
37C for 90 minutes to act as a positive control. Hoechstajp.amjpathol.org - The American Journal of Pathology
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concentration of 10 mg/mL and incubated for 10 minutes in
the dark. Cells were then visualized with a ﬂuorescence
microscope, and the proportion of apoptotic cell nuclei was
determined in four randomly chosen ﬁelds of each dish in
a blinded fashion. Each ﬁeld contained between 100 and
300 nuclei in total. The experiments were repeated four
times.
RT-PCR
Total RNA was isolated using the Qiagen RNeasy Mini-Kit
(Qiagen Ltd, Crawley, UK) by following the manufacturer’s
instructions. For extraction of RNA from tissue, 30 mg of
tissue was disrupted and homogenized in lysis buffer/
b-mercaptoethanol solution using a Potter’s homogenizer.
The resulting lysate was then transferred to a QiaShredder
and subsequently treated as previously described. Reverse
transcription and DNA ampliﬁcation steps were performed
concurrently in the same tube using the Promega Access
RT-PCR system (Promega) by following the manufacturer’s
instructions. Primer pairs were designed using the Primer 3
version 0.4.0 web-based primer design program (MIT,
Boston, MA), which were as follows: CACNA1G forward
50-CCTCTTCCGAGTCTCCACTG-30, reverse 50-TGGCC-
TCTTTGTTGCTTTCT-30; CACNA1H forward 50-GTAT-
GCGGATCCTGGTCACT-30, reverse 50-ACCCTCCTCC-
GTCTGGTAGT-30; CACNA1I forward 50-ACAACCCCT-
GGATGCTACTG-30, reverse 50-GCATAGTAGGGCAGC-
CTCTG-30; b-actin forward 50-CCCACACTGTGCCCATC-30
reverse 50-TGATCCACATCTGCTGGAAG-30. Samples were
ampliﬁed for 40 cycles and the products were separated on
a 1.5% agarose gel containing ethidium bromide and were
then imaged under ultraviolet light.
qPCR
Reverse transcription of RNA was performed using the
Omniscript reverse transcription kit (Qiagen) by following the
manufacturer’s instructions. Quantitative real-time PCR
(qPCR) of the resultant cDNA was performed using the Taq-
Man gene expression assay system (assay numbers: Cacna1g
Rn00581051_m1, Cacna1 hours Rn01460351_g1, Cacna1i
Rn01648788_m1), and was analyzed using the ABI Prism
7900HT machine (Applied Biosystems, Warrington, UK).
Glyceraldehyde-3-phosphate dehydrogenase (assay number
Rn99999916_s1) was used as an endogenous control gene after
initial studies conﬁrmed that its expression was not inﬂuenced
by disease induction. Samples were run in triplicate.
Immunocytochemistry
Polyclonal antibodies targeting Cav3.1 and Cav3.2 were
kindly donated by Leanne Cribbs (prepared against peptides
FVCQGEDTRNITNKSDCAEAS and YYCEGPDTRNIS-
TKAQCRAAH, respectively).9 Primary ratMCswerewashedThe American Journal of Pathology - ajp.amjpathol.orgtwice with PBS, ﬁxed in 95% ethanol with 5% glacial acetic
acid for 5 minutes, and then washed three times in PBS. Cells
were permeabilized by incubation with 0.5% Triton X-100 in
PBS for 10 minutes. After three more washes in PBS, cells
were blocked in 5% goat serum in PBS for 1 hour, and then
incubated with primary antibody (diluted 1 in 250 in PBS þ
0.1% Triton X-100) or with nonimmune rabbit IgG at 4C
overnight. Cells were again washed three times in PBS and
then incubated with a secondary antibody (Alexa Fluor 488
goat anti-rabbit antibody; Invitrogen) at a dilution of 1 in 1000
for 30 minutes. After three more washes, cells were counter-
stained, with DAPI at a ﬁnal concentration of 1 mg/mL for 15
minutes, and then visualized under a ﬂuorescent microscope.
Measurement of T-Type Current Inhibition by TH1177
The effects of TH1177 were measured in HEK cells stably
expressing Cav3.1 or Cav3.2 channels. T-type Ca
2þ currents
were measured using whole-cell voltage-clamping with an
Axopatch 200A controlled by pClamp software version 6.0
(Molecular Devices, Sunnyvale, CA). Currentswere recorded
via 1 to 2 MU pipettes at room temperature (approximately
22C) ﬁlled with a Csþ-rich pipette solution containing
120 mmol/L CsCl, 5 mmol/L MgCl2, 0.5 mmol/L CaCl2, 5
mmol/L Na2ATP, 0.3 mmol/L Na3GTP, 12 mmol/L EGTA,
and 10 mmol/L HEPES, pH 7.2, in combination with a bath
solution containing 138 mmol/L NaCl, 10 mmol/L HEPES,
20 mmol/L glucose, and 5 mmol/L CaCl2, pH 7.35. T-type
currents were recorded from a holding potential of 90 mV
during 200 msec steps to 20 mV.
In Vivo Experiments
Male Wistar rats weighing 200 to 250 g were housed with
free access to standard laboratory food and water. All
procedures were performed in accordance with the United
Kingdom Animals (Scientiﬁc Procedures) Act.
Isolation of Glomeruli
Freshly harvested kidneys were used for isolation of
glomeruli and subsequent RNA extraction for qPCR. All
steps were performed at 4C and all equipment and solutions
were pretreated to minimize RNase activity. Equipment was
soaked in 0.1 M NaOH for 60 minutes, then in 1 mmol/L
EDTA solution for another 60 minutes before being rinsed in
RNase free water. Solutions were made RNase-free by
treatment with 0.1% diethylpyrocarbonate overnight. The
diethylpyrocarbonate was then degraded by autoclaving.
The kidney capsules were removed and cortices were
dissected from each kidney. Cortical sections were then
minced with a razor blade and subsequently pressed through
a 180 mm pore size sieve. They were then rinsed through
successive sieves (106 mm then 63 mm pores) using ice cold
PBS. The tissue consisting of glomeruli on the 63 mm
mesh was collected and checked for purity using light393
Cove-Smith et almicroscopy. RNA was then extracted from the isolated
glomeruli using the Qiagen RNeasy Mini-Kit (Qiagen Ltd)
as previously described.
Treatment of Thy1 Nephritis
Thy1 nephritis was induced in 16 male Wistar rats Ox7
antibody (1 mg/kg, i.v.). Eight animals were treated with
intraperitoneal injections of TH1177 (dissolved in 100%
ethanol then diluted 10 times in PBS), starting on the day of
disease induction, at a dose of 20 mg/kg twice daily for the
ﬁrst 3 days and then 20 mg/kg once daily until sacriﬁce. The
other 8 rats were treated with equivalent injections of
vehicle (100% ethanol diluted 10 times in PBS). Sponta-
neously voided urine samples were collected on days 2 and
7 and were analyzed for protein:creatinine ratio. Half of
each group was sacriﬁced on day 7 and the other half on day
10. Organs were harvested for histological analysis and
serum samples taken by cardiac puncture to measure serum
creatinine.
Assessment of Severity of Glomerular Injury
Sections (4 mm) were cut and stained with H&E. A histo-
pathologist (N.D.) scored 30 glomeruli per section using the
following system: 0 Z normal appearance; 1 Z mesangial
expansion and/or hypercellularity; 2 Z microaneurysms,
necrosis, capsular hemorrhage, matrix or cellular crescents;
Total glomerular cell number and cross-sectional area were
quantiﬁed in 20 glomeruli per animal using NIS-Elements
Basic Research Software version 2.3 (Nikon, Kingston-on-
Thames, UK). All analyses were performed in a blinded
fashion.
Measurement of Serum Creatinine and Urinary
Protein:Creatinine Ratio
Blood samples were centrifuged to separate the serum from
the red cells. Urine samples were also centrifuged to remove
debris. The supernatants were collected and stored at
80C. All samples were then taken to the Biochemistry
Laboratory at King’s College Hospital (London, UK), and
they were analyzed using an automated system.
Immunostaining for Ki-67, ED1, and pERK
Sections (4 mm) of formalin-ﬁxed, parafﬁn-embedded tissue
were rehydrated with xylene and ethanol. Slides were heated
in citrate buffer pH 6 in a pressure cooker for 3 minutes.
Sections were washed in tris-buffered saline with 0.1%
tween-20, blocked in 10% goat serum for 30 minutes, and
then incubated with primary antibodies at a dilution of 1 in
100 (ED1, AbD Serotec, Kidlington, UK) and pERK (Cell
Signaling Technology, Boston, MA) incubated at 4C
overnight. Ki-67 (Leica Microsystems, Milton Keynes, UK)
was incubated at room temperature for 1 hour. After this,394slides were washed in TBST and then endogenous peroxide
activity was blocked with 2% hydrogen peroxide in meth-
anol for 15 minutes. After a further wash, a peroxidase-
conjugated goat anti-mouse secondary antibody (Dako
REAL EnVision Detection System; Dako, Ely, UK) was
applied to the slides for 30 minutes at room temperature.
The slides were washed, developed in Dako REAL DABþ
chromogen for 5 minutes, and then washed in water before
being counterstained with Haematoxylin and eosin, dehy-
drated in ethanols and xylene, and mounted. Positively
stained cells were counted in 30 glomeruli per section.
BP Recording
Male rats (weight, 200 to 250 g) were anesthetized with
2% isoﬂuorane in 2 litre O2 per minute with analgesia
(buprenorphine, 0.1 mg/kg). After routine laparotomy, the
catheter of the PhysioTel PA-C40 pressure transmitter
(Data Sciences International, St. Paul, MN) was surgically
implanted into the descending abdominal aorta and the
body of the probe was ﬁxed to the abdominal wall. After
1 week of recovery, rats housed in individual cages were
placed above the telemetric receivers with output to a
personal computer. Cardiovascular variables: systolic blood
pressure (BP), diastolic BP, mean arterial pressure, and
heart rate were monitored and recorded by scheduled
sampling for 10 seconds every 5 minutes until the end of
the protocol. After 7 days of baseline recording, rats were
treated with TH1177 as previously described. Control rats
received equivalent vehicle injections.
Statistics
Parametric variables were analyzed using a two-tailed
Student’s t-test (for comparison of two groups) or one-
way analysis of variance (for multiple group compari-
sons). For nonparametric variables, the signiﬁcance of the
difference between two groups was determined by a two-
tailed U-test and multiple groups compared using the
Kruskal-Wallis test. Differences were considered signiﬁ-
cant if P < 0.05. Statistical analyses were performed using
Prism software version 4.0 (Graph-Pad Software, San
Diego, CA).
Results
Pharmacological Inhibition of T-Type, But Not L-Type
Calcium Channels, Reduces Rat MC Proliferation in Vitro
The response of primary rat MCs to co-incubation with
nickel ions in vitro is illustrated in Figure 1A. There was
a signiﬁcant dose-dependent reduction in the percentage of
cells incorporating BrdU into their DNA (400 mmol/L v
control, P < 0.001). Figure 1B illustrates the effect of
TH1177 on rat MCs assessed by MTS assay and by BrdU
incorporation. In the MTS assay, an increase in cell numberajp.amjpathol.org - The American Journal of Pathology
Figure 1 The effect of pharmacological
calcium channel blockade on rat MC proliferation
and apoptosis in vitro. A: Representative images
of BrdU incorporation in primary rat MC co-
incubated with 400 mmol/L nickel chloride
(NiCl2). Toppanel: No drug and 400mmol/L NiCl2
show all nuclei stained with Hoechst. Bottom
panel: No drug and400mmol/LNiCl2 shownuclei
stained with anti-BrdU antibody. Graphical
representation of six independent experiments
showed a signiﬁcant dose-dependent reduction
in BrdU incorporation in rat MCs treated with
NiCl2. **P < 0.01, ***P < 0.001 versus control
cells.B, left panel: A signiﬁcant reduction in cell
number was seen in rat MCs incubated with
increasing concentrations of TH1177 for 72hours
(nZ 5). *P< 0.05, ***P< 0.001.Right panel:
BrdU incorporation was signiﬁcantly reduced
when these cells were exposed to TH1177 at10
mmol/L (n Z 3). *P < 0.05 versus vehicle-
treated control cells. C: Dose-response curve
demonstrated an ED50 of 15 mmol/L for the
anti-proliferative action of TH1177 in these
conditions. D: Co-incubation of rat MCs with
verapamil, an LCCB, had no effect on cell number
over 72 hours. E: Representative images of nuclei
stained with Hoechst. An example of the
apoptotic nucleus is indicated by the arrow in
the positive control image. The graph represents
four independent experiments demonstrating
that nickel (concentration of400 mmol/L) and
TH1177 (concentration of 20 mmol/L) caused
no increase in the proportion of apoptotic nuclei
seen compared to vehicle-treated cells.
T-Type Ca2þ Channels in Thy1 Nephritisfrom baseline was seen in all conditions, but the rate
decreased with increasing TH1177 concentration, leading to
a signiﬁcant dose-dependent reduction in cell number at
72 hours. There was also a dose-dependent reduction in
BrdU incorporation, reaching statistical signiﬁcance at
a concentration of 10 mmol/L (P < 0.05). An ED50 of
approximately 15 mmol/L can be estimated from these
experiments (Figure 1C). This anti-proliferative effect is not
seen when rat MCs are treated with verapamil at concentra-
tions that have been shown to completely abolish L-type
current (Figure 1D). There was no signiﬁcant increase in
apoptotic nuclei on co-incubation with TH1177 or NiCl2 (up
to concentrations of 20 mmol/L and 400 mmol/L), respectively
(Figure 1E). No increase in lactate dehydrogenase release was
demonstrated when rat MCs were incubated with these
concentrations of either drug (data not shown).The American Journal of Pathology - ajp.amjpathol.orgCav3.1 and Cav3.2 Are Co-Expressed in Rat Renal
Cortex, and Cav3.2 mRNA Levels Increase with
Increasing Disease Severity in Thy1 Nephritis
Figure 2A shows a representative gel demonstrating the
presence of PCR products for Cav3.1 and Cav3.2 from
whole rat kidney cortex mRNA. Some ampliﬁcation of
Cav3.3 mRNA is also detected, but this appears to be at
a lower level. These ﬁndings were conﬁrmed using qPCR
(with different primer sequences) as illustrated in Figure 2B.
Cav3.1 and Cav3.2 are detected at similar levels in normal
rat kidney, whereas very little Cav3.3 mRNA is present, in
keeping with the published literature reporting that it is
expressed almost exclusively in neuronal tissue.5 The level
of Cav3.2 mRNA increases signiﬁcantly in kidneys from
animals with Thy1 nephritis and this correlates with the395
Cove-Smith et alseverity of renal injury. No signiﬁcant change is seen in the
quantity of mRNA encoding for the other two isoforms in
this model. To further investigate the distribution of TCC
isoforms in rat kidney, glomeruli were isolated and the RNA
extracted from the glomerular fraction was compared to the
equivalent whole cortex extract. As illustrated in Figure 2C,
Cav3.1 mRNA predominates in glomeruli (12-fold higher
than the same isoform in cortical RNA; P < 0.001), whereas
Cav3.2 mRNA is primarily found in the nonglomerular
cortex (P < 0.01 versus glomerular extract). No signiﬁcant
difference is seen in Cav3.3 mRNA abundance between the
compartments, and this isoform remains at signiﬁcantly
lower levels than the other two. The primacy of Cav3.1 in rat
glomeruli is consistent with the ﬁnding that rat MCs (in
contrast to cultured human MCs) express Cav3.1, but not
Cav3.2, as demonstrated by PCR and immunocytochemistry
(Figure 2E).
Given the differential distribution of the two isoforms in
the rat kidney, we felt it was important to clarify the proﬁle396of TH1177 inhibitory activity on the individual a1-subunits.
This was performed on cloned human subunits expressed in
HEK cells. Cav3.1 is the more sensitive of the two isoforms
to TH1177 blockade, with an IC50 of 1.22  0.3 mmol/L in
this system, whereas Cav3.2 current is inhibited with an IC50
of 2.72  0.5 mmol/L (Figure 2D).
Treatment of Thy1 Nephritis with TH1177 Reduces
Glomerular Injury, Glomerular Area, and Glomerular
Cell Number
Figure 3A shows representative images of H&E-stained and
silver-stained sections of glomeruli from rats with Thy1
nephritis, treated with TH1177 or a vehicle. TH1177 treat-
ment leads to a signiﬁcant reduction in injury score from an
average of 39.5  2.0 in the placebo-treated Thy1 nephritis
group to 27.9  3.9 in the TH1177-treated Thy1 nephritis
group (P < 0.005) (Figure 3B). Further analysis of the
distribution of scores reveals signiﬁcantly fewer glomeruliFigure 2 Expression of T-type calcium channel
isoforms in the rat kidney. A: Representative gel
illustrating the presence of PCR products for T-type
calcium channel isoforms in RNA extracted from the
rat kidney cortex with rat brain extract as a positive
control. Products of the appropriate size were detec-
ted for Cav3.1 and Cav3.2, with some ampliﬁcation of
Cav3.3 also present, but apparently at a lower level.B,
left panel: Expression of T-type Ca2þ channel isoform
mRNA in normal rat kidneys (white bars) and in Thy1
nephritis (black bars). qPCR conﬁrmed the presence of
similar amounts of mRNA for Cav3.1 and Cav3.2 in
normal rat kidney (nZ 6), whereas minimal Cav3.3
expression was detected. **P < 0.01. Right panel:
Expression of T-type calcium channel isoformmRNA in
the renal cortex. The expression of Cav3.2 increases
signiﬁcantly in animals with Thy1 nephritis (nZ 18),
and this increase correlated with disease severity
(assessed by glomerular injury score). No association
was seen between disease severity and expression of
the other two isoforms. C: Expression of T-type
channel isoforms in glomeruli. Signiﬁcantly more
Cav3.1 mRNA was found in isolated glomeruli than in
the whole cortex, with no difference between normal
or diseased glomeruli. Cav3.2 mRNA expression
demonstrated the opposite pattern of distribution,
with signiﬁcantly more present in the whole cortex
than in the glomerular fraction. The increase in
expression of this isoform in disease occurred
primarily in the nonglomerular cortex. *P < 0.05,
**P < 0.01, and ***P < 0.001. D: Sensitivity of
cloned T-type calcium channel isoforms to TH1177.
Theability of TH1177 to inhibit T-type current through
cloned Cav3.1 and Cav3.2 subunits expressed in HEK
cells is illustrated. The IC50s for Cav3.1 and Cav3.2 can
be estimated as 1.22  0.3 mmol/L and 2.72  0.5
mmol/L, respectively. E: Primary rat MCs have
detectable mRNA for Cav3.1, but not for Cav3.2.
Consistently, immunocytochemistry of primary rat
MCs demonstrated stainingof all cellswith anti-Cav3.1
antibody, but minimal staining with anti-Cav3.2.
Equivalent concentration of nonimmune rabbit IgG
served as a negative control.
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(although not statistically signiﬁcant) increase in the
proportion with a normal appearance (Figure 3C). Average
glomerular area is signiﬁcantly lower in the TH1177-treated
group compared to the placebo-treated nephritic controls
(P < 0.05) (Figure 3B), as is the total glomerular cell
number (P < 0.005) (Figure 3D). The increase in glomer-
ular cellularity seen in placebo-treated Thy1 nephritis is
reduced by 49% with TH1177 treatment (normal glomeruli,
68.6  1.57; placebo-treated Thy1 nephritis group, 103.5 
3.42; TH1177-treated group, 86.4  2.81) (Figure 3E). Both
groups gained weight in an equivalent manner throughout
the experiment (data not shown).Treatment of Thy1 Nephritis with TH1177 Has No Effect
On Serum Creatinine or Urinary Protein:Creatinine
Ratio
Figure 4A shows the serum creatinine levels from normal
Wistar rats, rats with Thy1 nephritis treated with a vehicle,
and those treated with TH1177. This acute disease model
does not cause an increase in serum creatinine, which is an
insensitive measure of renal dysfunction. Therefore, there is
no difference between normal animals and those with
disease, or between the two treatment groups. Figure 4BFigure 3 Treatment of Thy1 nephritis with TH1177 reduces glomerular injur
TH1177-treated animals with Thy1 nephritis stained with H&E. Bottom panels: S
in the TH1177-treated group (average scoreZ 27.9  3.90) than the placebo gr
score in TH1177-treated kidneys (black bars) in comparison to placebo kidneys (
severely damaged group (score 2; evidence of necrosis, microaneurysms, crescen
in the proportion of glomeruli with a normal appearance (score 0), although this
increased signiﬁcantly with Thy1 nephritis compared to normal control kidneys
541.54 mm2; TH1177 group, 9020.8  461.77 mm2). E: Glomerular cell numbe
reduced signiﬁcantly in the TH1177 group (normal glomeruli, 68.6  1.57; pla
The American Journal of Pathology - ajp.amjpathol.orgillustrates the rise in proteinuria seen in both groups from
day 2 to day 7 after disease induction. There is no difference
in the level of proteinuria at either time point between the
treatment groups.
The Dose of TH1177 that Reduces Glomerular Cell
Proliferation in Thy1 Nephritis Has No Impact on
Systemic BP
Figure 4C shows results of intravascular BP recordings in
animals receiving TH1177 or a vehicle. Injections com-
menced at day 7 and continued until day 14. The initiation
of injections had no impact on systolic BP and there is no
signiﬁcant difference between the two groups.
Treatment of Thy1 Nephritis with TH1177 Reduces
Glomerular Cell Proliferation and Macrophage Number
Figure 5 shows representative images of Ki-67 staining in
normal kidney, placebo-treated Thy1 nephritis, and Thy1
nephritis treated with TH1177 (Figure 5, AeC, respectively).
Very few Ki-67-positive cells are seen in normal
glomeruli, in keeping with the quiescent nature of MCs
in the healthy kidney. The increase after disease induc-
tion is reduced signiﬁcantly by TH1177 (average numbery. A, Top panels: Representative images of glomeruli from placebo- and
tained with silver stain. B: Glomerular injury score was signiﬁcantly lower
oup (average scoreZ 39.5  2.03). C: The reduction in glomerular injury
white bars) reﬂects a reduction in the proportion of glomeruli in the most
t formation, or capsular hemorrhage). There was a corresponding increase
trend did not reach statistical signiﬁcance. **P < 0.01. D: Glomerular area
and this was reduced by TH1177 treatment (placebo group, 10765.5 
r also increased with disease induction, as expected. This increase was
cebo group, 103.5  3.42; TH1177 group, 86.4  2.81).
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Figure 4 Serum creatinine, urinary protein, and systolic BP are not
altered by TH1177 treatment in Thy1 nephritis. A: Serum creatinine was not
elevated in animals with acute Thy1 nephritis treated with placebo injec-
tions compared to normal controls, demonstrating that this acute model of
disease does not induce renal dysfunction, as assessed by the relatively
insensitive biomarker. There was also no impact of TH1177 treatment on
serum creatinine. B: Urinary protein:creatinine ratio increased signiﬁcantly
from day 2 to day 7 in both treatment groups. The lack of effect of TH1177
on proteinuria in our disease model was surprising, given its impact on
histological parameters of disease severity, suggesting that TH1177 was
not affecting the damage to the ﬁltration barrier itself, but more speciﬁ-
cally was acting on the mesangial cell response to disease. C: Graphical
representation of invasive systolic BP measurements of animals treated
with TH1177 (20 mg/kg) or equivalent vehicle injections from day 7 to day
14. There was no change in BP from pretreatment levels and no difference
was seen between the two groups.
Cove-Smith et alof Ki-67-positive cells per glomerulus in placebo-treated
Thy1 nephritis group versus the TH1177-treated group,
4.43  0.39 versus 2.13  0.50, respectively; P < 0.01)
(Figure 5J).
Results of immunostaining for ED1, a macrophage
marker, are also shown in Figure 5, DeF. Again, few
macrophages are seen in normal glomeruli, but their
numbers increase after induction of nephritis. Treatment
with TH1177 reduces the average number of ED1-positive398cells per glomerulus from 8.62  1.39 to 4.33  0.67 in
the placebo-treated Thy1 nephritis group (P < 0.01)
(Figure 5K).TH1177 Reduces ERK Activation in Thy1 Nephritis
The results of immunostaining for pERK are shown in
Figure 5, GeI. The number of cells exhibiting positive
staining for pERK increases in the glomeruli of animals
with Thy1 nephritis compared to normal kidneys. This is
signiﬁcantly attenuated by TH1177 treatment (average
number of pERK-expressing cells per glomerulus in
placebo-treated Thy1 nephritis group versus TH1177-
treated group, 6.56  0.77 versus 3.13  0.62, respec-
tively; P < 0.005) (Figure 5L).Discussion
These data demonstrate that TCC inhibition with two
independent agents inhibits primary rat MC proliferation
in vitro, whereas blockade of LCC has no effect. Further-
more, TH1177 treatment reduces glomerular injury and
glomerular cell proliferation in Thy1 nephritis at a dose that
does not lower systemic BP. These anti-proliferative actions
appear to involve modulation of the ERK signaling
pathway. These ﬁndings demonstrate that TCC blockade is
a useful strategy for studying and modifying MC prolifer-
ation in vivo, as well as in vitro.
Twenty years ago, Xu and Best8 ﬁrst identiﬁed an
association between T-type current and growth in atrial
myocytes. Cells isolated from rats with growth hormone-
secreting tumors had increased T-type current density
compared to controls. These changes preceded any increase
in heart weight or myocyte size, suggesting a causative role.
Since these early observational studies, there have been
a number of interventional experiments supporting the role
of TCC in proliferation. Rodman et al9 demonstrated
expression of the Cav3.1 isoform in pulmonary artery
myocytes. Knockdown of this isoform using ﬁve indepen-
dent siRNA sequences caused a reduction in proliferation
that appeared to correlate with the degree of knockdown
achieved. Overexpression of the Cav3.2 isoform in vascular
smooth muscle cells markedly increases their proliferative
rate.15 T-type currents have also been recorded in human
MCs and knockdown of the Cav3.2 isoform in these cells is
anti-proliferative. This is associated with an increase in the
proportion of cells in G1 and a reduction in S-phase, sug-
gesting a role for TCCs in facilitating progression across the
G1/S boundary of the cell cycle.10
The in vitro results presented here support a similar role
for TCCs in regulating rat MC proliferation. We cannot
exclude the possibility that TH1177 may affect ion channels
other than TCCs. However, published data in two different
prostate cancer cell lines demonstrate that TH1177 inhibits
inﬂux of extracellular calcium, but it has no effect onajp.amjpathol.org - The American Journal of Pathology
Figure 5 Treatment of Thy1 nephritis with TH1177
reduces glomerular cell proliferation, macrophage inﬁltra-
tion, and ERK activation. Representative images of kidneys
show they were immunostained for Ki-67 (AeC), ED1
(DeF), and pERK (GeI). Examples of positively stained
cells are marked with arrows. J: TH1177 treatment of Thy1
nephritis caused a signiﬁcant reduction in Ki-67-positive
nuclei per glomerulus. **P Z 0.007 versus placebo. K:
There were signiﬁcantly fewer ED1-positive cells in the
TH1177-treated group than the placebo group. **P Z
0.007. L: The reduction in glomerular cell proliferation was
paralleled by a 52% reduction in glomerular cells stained
positively for phosphorylated ERK. **P < 0.005 versus
placebo.
T-Type Ca2þ Channels in Thy1 Nephritiscalcium release from internal stores.6 LCCs are known to be
present in MCs and are an important pathway for the inﬂux
of extracellular calcium leading to MC contraction. Impor-
tantly, the anti-proliferative effect seen with TH1177 and
nickel is not found with concentrations of verapamil that are
known to completely abolish L-type current.16 Expression
of TRP channels in MCs has also been described,17 but
a comprehensive study of the expression of the individual
TRP channel isoforms and their role in MC proliferation has
not been undertaken and is beyond the scope of the current
study. These channels have been implicated in proliferation
in other cell types,18 and it is possible that these channels
also have a role in regulating the proliferative rate of MCs.
However, the use of two independent TCC blocking agents
that are unlikely to have overlapping off-target proﬁles,
along with the speciﬁcity of low concentrations of nickel for
TCCs over other ion channels, make TCC inhibition the
most likely mechanism of action in this study. Previous
work using siRNA to knockdown TCCs with high speci-
ﬁcity in human MCs also supports the role of these channels
in the regulation of MC proliferation.10
TCC inhibition has been shown to be nephroprotective in
a number of different animal models of renal disease.
Sugano et al19 studied subtotal nephrectomy in spontane-
ously hypertensive rats and found that the Cav3.1 isoform
was upregulated in glomeruli of diseased animals. SelectiveThe American Journal of Pathology - ajp.amjpathol.orgblockade of TCCs, using the R(-)-enantiomer of efonidi-
pine, reduced glomerular hypertrophy and interstitial
ﬁbrosis in this model. A study of renal injury in deoxy-
corticosterone acetate-salt hypertensive rats showed signif-
icant beneﬁt of mibefradil (a combined T and L-type
channel blocker) in comparison with amlodipine on
glomerular injury and proteinuria.20 This occurred despite
both agents reduction of systemic BP to the same degree.
Importantly, in this study both agents also equally reduced
glomerular capillary pressure, suggesting that the beneﬁt of
TCC blockade cannot be attributed solely to improved
intraglomerular hemodynamics. Mibefradil inhibits prolif-
eration of both rat (our unpublished observations) and
human MCs in vitro,10 and therefore may be exerting its
beneﬁcial effect in part by reduction of aberrant MC
proliferation in this model.
The in vivo data detailed here demonstrate that TH1177
reduces glomerular injury and glomerular cell proliferation
in acute Thy1 nephritis in rats. This occurs at doses that
have no impact on systemic BP, making it unlikely that this
dose of TH1177 has any signiﬁcant LCC blocking action in
these animals. These ﬁndings support the hypothesis that
TCC blockade inhibits MC proliferation in vivo, as well as
in vitro. Despite increasing interest in the involvement of
TCC in proliferation in a variety of cell types, the intra-
cellular signaling pathways responsible for mediating the399
Cove-Smith et aleffect of this tiny and transient Ca2þ inﬂux are poorly
understood. The mitogen-activated protein kinase cascade is
recognized as being a central pathway in mesangioproli-
ferative disease and inhibition of this pathway at various
levels has been shown to reduce MC proliferation.21,22
Moreover, extracellular calcium inﬂux is capable of stimu-
lating ERK signaling via protein kinase C, Pyk2, or CaM-
KII, as well as potentially through calmodulin-dependent
activation of Ras-GRF. The demonstration that TH1177
reduces the abundance of pERK in the glomeruli of animals
with Thy1 nephritis supports the hypothesis that its anti-
proliferative actions are mediated via suppression of this
signaling pathway. Further work is required to delineate the
exact mechanism by which calcium inﬂux through TCCs
inﬂuences ERK activation in glomeruli.
This work also demonstrates the novel ﬁnding of distinct
expression patterns of Cav3.1 and Cav3.2 TCC isoforms
within the rat kidney, and an isoform-speciﬁc response to
disease. The increase in expression of the Cav3.2 isoform in
Thy1 nephritis directly correlates with glomerular injury,
but surprisingly occurs predominantly in the nonglomerular
cortex. It is probable, therefore, that the correlation with
glomerular injury reﬂects a correlation of both parameters
with disease severity. TCC inhibition has been shown to
reduce proliferation in ﬁbroblasts23 and peripheral blood
mononuclear cells,24 as well as vascular smooth muscle
cells.14 Therefore, the increase in Cav3.2 expression may
be due, in part, to an inﬂux of leukocytes into the interstitial
compartment, or to activation and proliferation of resident
cells such as ﬁbroblasts. It is possible that TH1177 has
some impact on these cells in this disease. However, the
key pathology in this model is glomerular injury with
increased glomerular cellularity, and TH1177 has a clear
impact on this process. This is most likely due to a direct
effect on glomerular MC proliferation as demonstrated
in vitro.
It is important to note that although MC proliferation is
a key ﬁnding in diseases such as IgA nephropathy and
mesangiocapillary glomerulonephritis, there is some
controversy as to whether this is a causal process or simply
a response to the injury of other glomerular cells. In certain
circumstances, the proliferative response of MC to injury
may be necessary to allow repopulation and repair of the
glomerulus, as is seen in postinfectious glomerulonephritis.
Reducing MC proliferation in this setting may exacerbate
rather than ameliorate disease. However, a number of studies
have demonstrated that stimulating MC proliferation in vivo,
by administration ofmitogens such as platelet-derived growth
factor and basic ﬁbroblast growth factor, leads to glomerular
damage and increased matrix deposition. This suggests that
simply stimulating aberrant MC activation and proliferation
can induce a disease phenotype.25 Modiﬁcation of the
persistent activation of MC in the context of ongoing stimu-
lation (such as that seen in IgA nephropathy) is likely,
therefore, to be of beneﬁt, even if this is not the primary
pathological entity.26400The ﬁnding of predominant Cav3.1 expression in rat
glomeruli is in keeping with published data from Sugano
et al,19 but these authors did not describe the expression
patterns of the other isoforms in this model. This is also
consistent with our observation that Cav3.1 is themain isoform
identiﬁed in primary rat MCs in culture, in contrast to primary
human MCs, which express the Cav3.2 isoform only.
10 This
suggests that there is an interspecies variation in the expression
of TCC isoforms, which may become an important consider-
ation as isoform-speciﬁc T-type inhibitors are developed and
tested with the ultimate aim of clinical application. TH1177
inhibits both of the TCC isoforms found in the rat kidney
cortex, but with a higher afﬁnity for Cav3.1 blockade, sug-
gesting that this may be the key target for the amelioration of
glomerular injury by TH1177 in this disease model.
We have found that TH1177 reduces glomerular cell
proliferation in vivo, as well as in vitro. Further work is
needed to clarify the exact roles of the different TCC iso-
forms and their downstream signaling pathways in renal
disease to provide information for the development and
study of appropriate selective TCC inhibitors. Studies in
chronic disease models in animals, as well as large clinical
trials with long-term follow-up, are needed to determine
whether TCC inhibitors are superior to LCC blockers in
slowing the progression of chronic kidney disease.Limitations of This Study
Although we have demonstrated distinct expression of
Cav3.1 and Cav3.2 in the rat kidney at the RNA level,
attempts to delineate their exact localization using immu-
nohistochemistry have been unsuccessful in our hands. The
existing antibodies that we have worked with have a degree
of cross-reactivity between isoforms and have produced
conﬂicting results when used on tissue sections and in
Western blot analysis. Therefore, we cannot conﬁdently say
that the expression of T-type channel protein mirrors the
changes seen in mRNA.References
1. Pabst R, Sterzel RB: Cell renewal of glomerular cell types in normal
rats. An autoradiographic analysis. Kidney Int 1983, 24:626e631
2. Jaber BL, Madias NE: Progression of chronic kidney disease: can it be
prevented or arrested? Am J Med 2005, 118:1323e1330
3. Saleh H, Schlatter E, Lang D, Pauels HG, Heidenreich S: Regulation of
mesangial cell apoptosis and proliferation by intracellular Ca(2þ)
signals. Kidney Int 2000, 58:1876e1884
4. Orth SR, Nobiling R, Bonisch S, Ritz E: Inhibitory effect of calcium
channel blockers on human mesangial cell growth: evidence for actions
independent of L-type Ca2þ channels. Kidney Int 1996, 49:868e879
5. Perez-Reyes E: Three for T: Molecular analysis of the low voltage-
activated calcium channel family. Cell Mol Life Sci 1999, 56:660e669
6. Haverstick DM, Heady TN, Macdonald TL, Gray LS: Inhibition of
human prostate cancer proliferation in vitro and in a mouse model by
a compound synthesized to block Ca2þ entry. Cancer Res 2000, 60:
1002e1008ajp.amjpathol.org - The American Journal of Pathology
T-Type Ca2þ Channels in Thy1 Nephritis7. Guo W, Kamiya K, Kodama I, Toyama J: Cell cycle-related changes in
the voltage-gated Ca2þ currents in cultured newborn rat ventricular
myocytes. J Mol Cell Cardiol 1998:1095e1103
8. Xu XP, Best PM: Increase in T-type calcium current in atrial myocytes
from adult rats with growth hormone-secreting tumors. Proc Natl Acad
Sci USA 1990, 87:4655e4659
9. Rodman DM, Reese K, Harral J, Fouty B, Wu S, West J, Hoedt-
Miller M, Tada Y, Li KX, Cool C, Fagan K, Cribbs L: Low-voltage-
activated (T-type) calcium channels control proliferation of human
pulmonary artery myocytes. Circ Res 2005, 96:864e872
10. Mulgrew CJ, Cove-Smith A, McLatchie LM, Brooks G, Shattock MJ,
Hendry BM: Inhibition of human mesangial cell proliferation by tar-
geting T-type calcium channels. Nephron Exp Nephrol 2009, 113:
e77ee88
11. Linz P WS, Amann K, Hilgers KF, Veelken R: Is there a role for
T-type Ca-channels of mesangial cells cultured in high glucose media?
(abstract) J Am Soc Nephrol 2004:727A
12. Aguas AP, Nickerson PA: Effect of verapamil on blood pressure and
lesions in heart and kidney of rats made hypertensive by deoxy-
corticosterone (DOC). Am J Pathol 1983, 110:48e54
13. Gaber L, Walton C, Brown S, Bakris G: Effects of different antihy-
pertensive treatments on morphologic progression of diabetic nephrop-
athy in uninephrectomized dogs. Kidney Int 1994, 46:161e169
14. Moriyama T, Oka K, Ueda H, Imai E: Nilvadipine attenuates mesan-
gial expansion and glomerular hypertrophy in diabetic db/db mice,
a model for type 2 diabetes. Clin Exp Nephrol 2004, 8:230e236
15. Brooks GHJ, Bates SE: Over-expression of the voltage-gated T-type
calcium channel induces vascular smooth muscle cell proliferation
(abstract). Circulation 1999, 100:1e209
16. Kuga T, Sadoshima J, Tomoike H, Kanaide H, Akaike N,
Nakamura M: Actions of Ca2þ antagonists on two types of Ca2þ
channels in rat aorta smooth muscle cells in primary culture. Circ Res
1990, 67:469e480
17. Sours S, Du J, Chu S, Ding M, Zhou XJ, Ma R: Expression of canonical
transient receptor potential (TRPC) proteins in human glomerular
mesangial cells. Am J Physiol Renal Physiol 2006, 290:F1507eF1515The American Journal of Pathology - ajp.amjpathol.org18. Zeng B, Yuan C, Yang X, Atkin SL, Xu SZ: TRPC channels and
their splice variants are essential for promoting human ovarian cancer
cell proliferation and tumorigenesis. Curr Cancer Drug Targets 2013,
13:103e116
19. Sugano N, Wakino S, Kanda T, Tatematsu S, Homma K, Yoshioka K,
Hasegawa K, Hara Y, Suetsugu Y, Yoshizawa T, Utsunomiya Y,
Tokudome G, Hosoya T, Saruta T, Hayashi K: T-type calcium channel
blockade as a therapeutic strategy against renal injury in rats with
subtotal nephrectomy. Kidney Int 2008, 73:826e834
20. Baylis C, Qiu C, Engels K: Comparison of L-type and mixed L- and
T-type calcium channel blockers on kidney injury caused by
deoxycorticosterone-salt hypertension in rats. Am J Kidney Dis 2001,
38:1292e1297
21. Bokemeyer D, Panek D, Kramer HJ, Lindemann M, Kitahara M,
Boor P, Kerjaschki D, Trzaskos JM, Floege J, Ostendorf T: In vivo
identiﬁcation of the mitogen-activated protein kinase cascade as
a central pathogenic pathway in experimental mesangioproliferative
glomerulonephritis. J Am Soc Nephrol 2002, 13:1473e1480
22. Clarke HC, Kocher HM, Khwaja A, Kloog Y, Cook HT, Hendry BM:
Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular
cellular proliferation and macrophage number in rat thy-1 nephritis.
J Am Soc Nephrol 2003, 14:848e854
23. Wang Z, Estacion M, Mordan LJ: Ca2þ inﬂux via T-type channels
modulates PDGF-induced replication of mouse ﬁbroblasts. Am J
Physiol 1993, 265:C1239eC1246
24. Lijnen P, Fagard R, Petrov V: Mibefradil-induced inhibition of
proliferation of human peripheral blood mononuclear cells. J Car-
diovasc Pharmacol 1999, 33:595e604
25. Floege J, Eng E, Young BA, Alpers CE, Barrett TB, Bowen-Pope DF,
Johnson RJ: Infusion of platelet-derived growth factor or basic ﬁbro-
blast growth factor induces selective glomerular mesangial cell
proliferation and matrix accumulation in rats. J Clin Invest 1993, 92:
2952e2962
26. Johnson RJ, Floege J, Yoshimura A, Iida H, Couser WG, Alpers CE:
The activated mesangial cell: a glomerular “myoﬁbroblast”? J Am Soc
Nephrol 1992, 2:S190eS197401
